Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: An in vivo study in swine

Journal of Thoracic and Cardiovascular Surgery

Volumn 136, Issue 4, 2008, Pages 908-914

  McKellar, Stephen H ^a   Thompson III, Jess L ^a   Garcia Rinaldi, Raul F ^b   MacDonald, Ryan J ^a   Sundt III, Thoralf M ^a   Schaff, Hartzell V ^a  

^a MAYO CLINIC   (United States)

^b Advanced Cardiology Center Puerto Rico   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; SWINE; THROMBOCYTE AGGREGATION; THROMBOSIS PREVENTION;

ADMINISTRATION, ORAL; ANIMALS; ASPIRIN; BIOPROSTHESIS; DALTEPARIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEART VALVE PROSTHESIS IMPLANTATION; INJECTIONS, SUBCUTANEOUS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RANDOM ALLOCATION; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; SWINE; THROMBOEMBOLISM; THROMBOLYTIC THERAPY; TICLOPIDINE; TIME FACTORS;

EID: 54049137962     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.01.045     Document Type: Article

References (28)

1. Emery R.W., Krogh C.C., Arom K.V., Emery A.M., Benyo-Albrecht K., Joyce L.D., et al. The St. Jude Medical cardiac valve prosthesis: a 25-year experience with single valve replacement. Ann Thorac Surg 79 (2005) 776-783
2. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
3. Turpie A.G., Eriksson B.I., Lassen M.R., and Bauer K.A. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol 10 (2003) 327-332
4. O'Brien C.L., and Gage B.F. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293 (2005) 699-706
5. Heit J.A., Colwell C.W., Francis C.W., Ginsberg J.S., Berkowitz S.D., Whipple J., et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 161 (2001) 2215-2221
6. Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4 (2006) 121-128
7. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
8. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
9. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
10. Bertrand M.E., Rupprecht H.J., Urban P., and Gershlick A.H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
11. McKellar S.H., Thompson J.L., and Schaff H.V. A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses. J Surg Res 141 (2007) 1-6
12. Salerno C.T., Droel J., and Bianco R.W. Current state of in vivo preclinical heart valve evaluation. J Heart Valve Dis 7 (1998) 158-162
13. Thompson J.L., Hamner C.E., Potter D.D., Lewin M., Sundt T.M., and Schaff H.V. Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model. J Thorac Cardiovasc Surg 134 (2007) 359-365
14. Jayachandran M., Okano H., Chatrath R., Owen W.G., McConnell J.P., and Miller V.M. Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs. J Appl Physiol 97 (2004) 1445-1452
15. Ribeiro P.A., Al Zaibag M., Idris M., Al Kasab S., Davies G., Mashat E., et al. Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with rheumatic heart disease. J Thorac Cardiovasc Surg 91 (1986) 92-98
16. Hartz R.S., LoCicero III J., Kucich V., DeBoer A., O'Mara S., Meyers S.N., et al. Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position. J Thorac Cardiovasc Surg 92 (1986) 684-690
17. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
18. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., and Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
19. Schlitt A., von Bardeleben R.S., Ehrlich A., Eimermacher A., Peetz D., Dahm M., et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 109 (2003) 131-135
20. Jaremo P., Starkhammar C., Lundstrom A., Lindahl T.L., and Richter A. Inverse relationship between the severity of gingivitis and platelet reactivity in stable angina pectoris. J Thromb Haemost 5 (2007) 422-423
21. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
22. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
23. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
24. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
25. Garcia-Rinaldi R. Clopidogrel-aspirin inhibit the thrombogenicity of St. Jude mechanical aortic prostheses. Ann Thorac Surg 81 (2006) 787-788
26. Garcia-Rinaldi R. Clopidogrel-ASA combination inhibits the thrombogenicity of St. Jude Medical mechanical Aortic Prostheses. Available at: http://www.ctsnet.org/doc/9565. Accessed 12-3-2007.
27. Hobson A.R., Agarwala R.A., Swallow R.A., Dawkins K.D., and Curzen N.P. Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets 17 (2006) 509-518
28. Tiede D.J., Nishimura R.A., Gastineau D.A., Mullany C.J., Orszulak T.A., and Schaff H.V. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 73 (1998) 665-680